{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:46:22Z","timestamp":1791362782547,"version":"4.3.1"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["39\u201343"],"award-info":[{"award-number":["39\u201343"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.bone.2020.115715","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T13:22:57Z","timestamp":1603804977000},"page":"115715","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Clodronate"],"prefix":"10.1016","volume":"143","author":[{"given":"Eugene","family":"McCloskey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander H.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Powles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3899","key":"10.1016\/j.bone.2020.115715_bb0005","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1126\/science.165.3899.1262","article-title":"Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo","volume":"165","author":"Fleisch","year":"1969","journal-title":"Science"},{"issue":"8141","key":"10.1016\/j.bone.2020.115715_bb0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(79)91551-4","article-title":"Effects of disodium dichloromethylene diphosphonate on Paget\u2019s disease of bone","volume":"2","author":"Meunier","year":"1979","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0015","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/BF00217308","article-title":"Elimination of phagocytic cells in the spleen after intravenous injection of liposome-encapsulated dichloromethylene diphosphonate. An enzyme-histochemical study","volume":"238","author":"van Rooijen","year":"1984","journal-title":"Cell Tissue Res."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0923-2494(92)80169-L","article-title":"Liposome-mediated elimination of macrophages","volume":"143","author":"van Rooijen","year":"1992","journal-title":"Res. Immunol."},{"issue":"5 Pt 1","key":"10.1016\/j.bone.2020.115715_bb0025","first-page":"L819","article-title":"Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections","volume":"270","author":"Hashimoto","year":"1996","journal-title":"Am. J. Phys."},{"issue":"9","key":"10.1016\/j.bone.2020.115715_bb0030","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/rheumatology\/38.9.818","article-title":"Liposomal clodronate eliminates synovial macrophages, reduces inflammation and ameliorates joint destruction in antigen-induced arthritis","volume":"38","author":"Richards","year":"1999","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bone.2020.115715_bb0035","doi-asserted-by":"crossref","first-page":"101121","DOI":"10.1016\/j.redox.2019.101121","article-title":"LRP1 activation attenuates white matter injury by modulating microglial polarization through Shc1\/PI3K\/Akt pathway after subarachnoid hemorrhage in rats","volume":"21","author":"Peng","year":"2019","journal-title":"Redox Biol."},{"issue":"8","key":"10.1016\/j.bone.2020.115715_bb0040","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.neo.2019.05.006","article-title":"Clodronate-liposome mediated macrophage depletion abrogates multiple myeloma tumor establishment in vivo","volume":"21","author":"Opperman","year":"2019","journal-title":"Neoplasia"},{"issue":"9","key":"10.1016\/j.bone.2020.115715_bb0045","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1359\/jbmr.1997.12.9.1358","article-title":"Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5\u2032-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro","volume":"12","author":"Frith","year":"1997","journal-title":"J. Bone Miner. Res."},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0050","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S8756-3282(01)00412-4","article-title":"Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro","volume":"28","author":"Benford","year":"2001","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2020.115715_bb0055","first-page":"3007","article-title":"Inhibition by diphosphonates of bone resorption induced by the Walker tumor of the rat","volume":"44","author":"Jung","year":"1984","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.bone.2020.115715_bb0060","first-page":"1471","article-title":"Dichloromethylene diphosphonate (Cl2MDP) treatment of hypercalcaemia produced from bone metastases (author\u2019s transl)","volume":"11","author":"Delmas","year":"1982","journal-title":"Nouv. Press. Med."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0065","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jcem-54-4-837","article-title":"Long term effects of dichloromethylene diphosphonate in Paget\u2019s disease of bone","volume":"54","author":"Delmas","year":"1982","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0070","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0221-8747(82)90013-3","article-title":"Long-term effects of dichloromethylene diphosphonate (CI2MDP) on skeletal lesions in multiple myeloma","volume":"4","author":"Delmas","year":"1982","journal-title":"Metab. Bone Dis. Relat. Res."},{"issue":"10","key":"10.1016\/j.bone.2020.115715_bb0075","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/art.1780231017","article-title":"Biochemical and clinical responses to dichloromethylene diphosphonate (Cl2MDP) in Paget\u2019s disease of bone","volume":"23","author":"Douglas","year":"1980","journal-title":"Arthritis Rheum."},{"issue":"8177","key":"10.1016\/j.bone.2020.115715_bb0080","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(80)91496-8","article-title":"Effect of dichloromethylene diphosphonate in Paget\u2019s disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease","volume":"1","author":"Douglas","year":"1980","journal-title":"Lancet"},{"issue":"6365","key":"10.1016\/j.bone.2020.115715_bb0085","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1136\/bmj.286.6365.587","article-title":"Drug treatment of primary hyperparathyroidism: use of clodronate disodium","volume":"286","author":"Douglas","year":"1983","journal-title":"Br. Med. J. (Clin. Res. Ed.)"},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0090","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1365-2141.1983.tb02074.x","article-title":"The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma","volume":"54","author":"Paterson","year":"1983","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.bone.2020.115715_bb0095","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1002\/1097-0142(19811015)48:8<1922::AID-CNCR2820480833>3.0.CO;2-2","article-title":"Parenteral diphosphonates for treating malignant hypercalcemia","volume":"48","author":"Jung","year":"1981","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1056\/NEJM198108063050612","article-title":"Use of dichloromethylene diphosphonate in metastatic bone disease","volume":"305","author":"Jung","year":"1981","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0105","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJM198002073020602","article-title":"Effects of dichloromethylene diphosphonate on skeletal mobilization of calcium in multiple myeloma","volume":"302","author":"Siris","year":"1980","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0110","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7326\/0003-4819-94-3-312","article-title":"Hypercalcemia of malignancy: treatment with intravenous dichloromethylene diphosphonate","volume":"94","author":"Jacobs","year":"1981","journal-title":"Ann. Intern. Med."},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0115","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0002-9343(82)90855-5","article-title":"Therapy of hypercalcemia due to parathyroid carcinoma with intravenous dichloromethylene diphosphonate","volume":"72","author":"Shane","year":"1982","journal-title":"Am. J. Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0120","first-page":"107","article-title":"Tolerability and safety of clodronate therapy in bone diseases","volume":"11","author":"Mian","year":"1991","journal-title":"Int. J. Clin. Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0125","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2165\/00002018-199614030-00003","article-title":"Adverse effects of bisphosphonates. A comparative review","volume":"14","author":"Adami","year":"1996","journal-title":"Drug Saf."},{"issue":"8317","key":"10.1016\/j.bone.2020.115715_bb0130","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0140-6736(83)92755-1","article-title":"Long-term controlled trial with diphosphonate in patients with osteolytic bone metastases","volume":"1","author":"Elomaa","year":"1983","journal-title":"Lancet"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2020.115715_bb0135","first-page":"S53","article-title":"Treatment of skeletal disease in breast cancer: a controlled clodronate trial","volume":"8","author":"Elomaa","year":"1987","journal-title":"Bone"},{"issue":"8827","key":"10.1016\/j.bone.2020.115715_bb0140","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Finnish Leukaemia Group","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0145","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1200\/JCO.1997.15.4.1341","article-title":"Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients","volume":"15","author":"Saarto","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0150","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/bjc.1997.105","article-title":"Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens","volume":"75","author":"Saarto","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1200\/JCO.2001.19.1.10","article-title":"Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial","volume":"19","author":"Saarto","year":"2001","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0160","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br. J. Haematol."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0165","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1046\/j.1365-2141.1999.01194.x","article-title":"Economic impact of using clodronate in the management of patients with multiple myeloma","volume":"104","author":"Bruce","year":"1999","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0170","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br. J. Haematol."},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0175","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.bone.2020.115715_bb0180","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1093\/jnci\/90.9.704","article-title":"Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer","volume":"90","author":"Powles","year":"1998","journal-title":"J. Natl. Cancer Inst."},{"issue":"15","key":"10.1016\/j.bone.2020.115715_bb0185","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0190","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0195","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S8756-3282(00)00437-3","article-title":"Effects of clodronate on vertebral fracture risk in osteoporosis: a 1-year interim analysis","volume":"28","author":"McCloskey","year":"2001","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0200","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1359\/jbmr.040116","article-title":"Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study","volume":"19","author":"McCloskey","year":"2004","journal-title":"J. Bone Miner. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0205","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1359\/jbmr.061008","article-title":"Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study","volume":"22","author":"McCloskey","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"12","key":"10.1016\/j.bone.2020.115715_bb0210","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s00198-009-0942-x","article-title":"Can fall risk be incorporated into fracture risk assessment algorithms: a pilot study of responsiveness to clodronate","volume":"20","author":"Kayan","year":"2009","journal-title":"Osteoporos. Int."},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0215","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1007\/s00198-008-0786-9","article-title":"Ten-year fracture probability identifies women who will benefit from clodronate therapy\u2014additional results from a double-blind, placebo-controlled randomised study","volume":"20","author":"McCloskey","year":"2009","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2020.115715_bb0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1600-0609.1989.tb01506.x","article-title":"Treatment of painful bone lesions and hypercalcemia","volume":"51","author":"Ascari","year":"1989","journal-title":"Eur. J. Haematol. Suppl."},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0225","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/hon.2900080104","article-title":"Long-term effects of parenteral dichloromethylene bisphosphonate (CL2MBP) on bone disease of myeloma patients treated with chemotherapy","volume":"8","author":"Merlini","year":"1990","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0230","first-page":"833","article-title":"A prospective, controlled, nonrandomized study on prophylactic parenteral dichloromethylene bisphosphonate (clodronate) in multiple-myeloma","volume":"5","author":"Riccardi","year":"1994","journal-title":"Int. J. Oncol."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0235","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000226904","article-title":"Controlled clinical study on the use of dichloromethylene diphosphonate in patients with breast carcinoma metastasizing to the skeleton","volume":"48","author":"Martoni","year":"1991","journal-title":"Oncology"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2020.115715_bb0240","first-page":"S35","article-title":"Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man","volume":"8","author":"McCloskey","year":"1987","journal-title":"Bone"},{"key":"10.1016\/j.bone.2020.115715_bb0245","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/00003086-198704000-00011","article-title":"Long-term follow-up observations on treatment in Paget\u2019s disease of bone","volume":"217","author":"Kanis","year":"1987","journal-title":"Clin. Orthop."},{"issue":"245","key":"10.1016\/j.bone.2020.115715_bb0250","first-page":"755","article-title":"Duration of effect of oral diphosphonate therapy in Paget\u2019s disease of bone","volume":"64","author":"Gray","year":"1987","journal-title":"Q. J. Med."},{"issue":"8444","key":"10.1016\/j.bone.2020.115715_bb0255","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1016\/S0140-6736(85)92253-6","article-title":"Intravenous clodronate in the treatment and retreatment of Paget\u2019s disease of bone","volume":"1","author":"Yates","year":"1985","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0260","first-page":"325","article-title":"Sustained biochemical effects of short treatment of Paget\u2019s disease of bone with dichloromethylene diphosphonate","volume":"4","author":"Chapuy","year":"1983","journal-title":"Metab. Bone Dis. Relat. Res."},{"issue":"4\u20135","key":"10.1016\/j.bone.2020.115715_bb0265","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0221-8747(81)90049-7","article-title":"Paget\u2019s disease: improvement of spinal cord dysfunction with diphosphonates and calcitonin","volume":"3","author":"Douglas","year":"1981","journal-title":"Metab. Bone Dis. Relat. Res."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0270","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1302\/0301-620X.63B4.6457839","article-title":"Spinal cord dysfunction in Paget\u2019s disease of bone. Has medical treatment a vascular basis?","volume":"63B","author":"Douglas","year":"1981","journal-title":"J. Bone Joint Surg. (Br.)"},{"key":"10.1016\/j.bone.2020.115715_bb0275","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/978-1-4615-9167-2_35","article-title":"Effects of disodium dichloromethylene diphosphonate (CL2MDP) on Paget\u2019s disease of bone","volume":"128","author":"Meunier","year":"1980","journal-title":"Adv. Exp. Med. Biol."},{"issue":"48","key":"10.1016\/j.bone.2020.115715_bb0280","first-page":"1822","article-title":"Treatment of hypercalcemia of tumoral origin with two diphosphonates","volume":"110","author":"Jung","year":"1980","journal-title":"Schweiz Med Wochenschr"},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0285","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI109780","article-title":"Effects of disodium dichloromethylene diphosphonate on hypercalcemia produced by bone metastases","volume":"65","author":"Chapuy","year":"1980","journal-title":"J. Clin. Invest."},{"issue":"7\u20138","key":"10.1016\/j.bone.2020.115715_bb0290","first-page":"651","article-title":"Iv dichloromethylene diphosphonate in cancer-associated hypercalcemia: a phase I-II evaluation","volume":"65","author":"Cohen","year":"1981","journal-title":"Cancer Treat. Rep."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/0002-9343(82)90813-0","article-title":"Comparison of two parenteral diphosphonates in hypercalcemia of malignancy","volume":"72","author":"Jung","year":"1982","journal-title":"Am. J. Med."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0300","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/0002-9343(83)90958-0","article-title":"Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton","volume":"74","author":"Siris","year":"1983","journal-title":"Am. J. Med."},{"issue":"4\u20135","key":"10.1016\/j.bone.2020.115715_bb0305","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF02405086","article-title":"The effects of dichloromethylene diphosphonate on hypercalcemia and other parameters of the humoral hypercalcemia of malignancy in the rat Leydig cell tumor","volume":"35","author":"Martodam","year":"1983","journal-title":"Calcif. Tissue Int."},{"issue":"8410","key":"10.1016\/j.bone.2020.115715_bb0310","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/S0140-6736(84)91143-7","article-title":"Disodium clodronate effective in management of severe hypercalcaemia caused by parathyroid carcinoma","volume":"2","author":"Jungst","year":"1984","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0315","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1177\/030089168507100109","article-title":"Hypercalcemia in malignancies: treatment with dichloromethylene diphosphonate (Cl2MDP)","volume":"71","author":"Conte","year":"1985","journal-title":"Tumori"},{"issue":"8481","key":"10.1016\/j.bone.2020.115715_bb0320","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(86)92834-5","article-title":"Effects of diphosphonates in hypercalcaemia due to neoplasia","volume":"1","author":"Kanis","year":"1986","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0325","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/archinte.147.5.937","article-title":"Clodronate. A randomized study in the treatment of cancer-related hypercalcemia","volume":"147","author":"Witte","year":"1987","journal-title":"Arch. Intern. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2020.115715_bb0330","first-page":"S43","article-title":"Treatment of the hypercalcaemia of malignancy with intravenous clodronate","volume":"8","author":"Urwin","year":"1987","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0335","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.0954-6820.1987.tb01285.x","article-title":"Clodronate treatment in patients with malignancy-associated hypercalcemia","volume":"221","author":"Rastad","year":"1987","journal-title":"Acta Med. Scand."},{"issue":"11","key":"10.1016\/j.bone.2020.115715_bb0340","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1001\/archinte.1987.00370110184032","article-title":"Results of a randomized study of clodronate in treating cancer-related hypercalcemia","volume":"147","author":"Peck","year":"1987","journal-title":"Arch. Intern. Med."},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0345","first-page":"395","article-title":"The use of dichloromethylene bisphosphonate and aminobutane bisphosphonate in hypercalcemia of malignancy","volume":"2","author":"Adami","year":"1987","journal-title":"Bone Miner."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0350","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/8756-3282(88)90001-4","article-title":"Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate","volume":"9","author":"Bonjour","year":"1988","journal-title":"Bone"},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0355","first-page":"655","article-title":"Long-term effects of dichloromethylene diphosphonate in patients with osteolytic bone metastases and coincident primary hyperparathyroidism","volume":"68","author":"Elomaa","year":"1984","journal-title":"Cancer Treat. Rep."},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0360","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/8756-3282(96)00075-0","article-title":"Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer","volume":"18","author":"Rizzoli","year":"1996","journal-title":"Bone"},{"issue":"7","key":"10.1016\/j.bone.2020.115715_bb0365","first-page":"701","article-title":"Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases","volume":"88","author":"Tubiana-Hulin","year":"2001","journal-title":"Bull. Cancer"},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0370","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2796.1999.00507.x","article-title":"Oral clodronate in breast cancer patients with bone metastases: a randomized study","volume":"246","author":"Kristensen","year":"1999","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.bone.2020.115715_bb0375","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0380","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S8756-3282(96)00285-2","article-title":"Clodronate decreases the frequency of skeletal metastases in women with breast cancer","volume":"19","author":"Kanis","year":"1996","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0385","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1056\/NEJM199808063390601","article-title":"Reduction in new metastases in breast cancer with adjuvant clodronate treatment","volume":"339","author":"Diel","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"4 Suppl 11","key":"10.1016\/j.bone.2020.115715_bb0390","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0093-7754(01)90237-4","article-title":"Bisphosphonates in the prevention of bone metastases: current evidence","volume":"28","author":"Diel","year":"2001","journal-title":"Semin. Oncol."},{"issue":"7","key":"10.1016\/j.bone.2020.115715_bb0395","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol."},{"issue":"10001","key":"10.1016\/j.bone.2020.115715_bb0400","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","article-title":"Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials","volume":"386","year":"2015","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0405","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdv617","article-title":"Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel","volume":"27","author":"Hadji","year":"2016","journal-title":"Ann. Oncol."},{"issue":"18","key":"10.1016\/j.bone.2020.115715_bb0410","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1200\/JCO.2016.70.7257","article-title":"Use of adjuvant bisphosphonates and other bone-modifying agents in breast cancer: a Cancer Care Ontario and American Society of Clinical Oncology clinical practice guideline","volume":"35","author":"Dhesy-Thind","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0415","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2141.1994.tb06730.x","article-title":"Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma, Finnish Leukaemia Group","volume":"87","author":"Laakso","year":"1994","journal-title":"Br. J. Haematol."},{"issue":"9757","key":"10.1016\/j.bone.2020.115715_bb0420","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC myeloma IX): a randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"10.1016\/j.bone.2020.115715_bb0425","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bone.2020.115715_bb0430","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1997.488","article-title":"Concomitant i.v. and oral clodronate in the relief of bone pain\u2014a double-blind placebo-controlled study in patients with prostate cancer","volume":"76","author":"Kylmala","year":"1997","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0435","first-page":"316","article-title":"The effect of combined intravenous and oral clodronate treatment on bone pain in patients with metastatic prostate cancer","volume":"83","author":"Kylmala","year":"1994","journal-title":"Ann. Chir. Gynaecol."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0440","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/j.1464-410X.1995.tb07715.x","article-title":"Pain relief and quality-of-life assessment following intravenous and oral clodronate in hormone-escaped metastatic prostate cancer","volume":"76","author":"Cresswell","year":"1995","journal-title":"Br. J. Urol."},{"issue":"17","key":"10.1016\/j.bone.2020.115715_bb0445","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1200\/JCO.2003.03.042","article-title":"Randomized, double-blind, controlled trial of mitoxantrone\/prednisone and clodronate versus mitoxantrone\/prednisone and placebo in patients with hormone-refractory prostate cancer and pain","volume":"21","author":"Ernst","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.bone.2020.115715_bb0450","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1093\/jnci\/djg038","article-title":"A double-blind, placebo-controlled, randomized trial of oral sodium clodronate for metastatic prostate cancer (MRC PR05 trial)","volume":"95","author":"Dearnaley","year":"2003","journal-title":"J. Natl. Cancer Inst."},{"issue":"9","key":"10.1016\/j.bone.2020.115715_bb0455","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol."},{"issue":"10","key":"10.1016\/j.bone.2020.115715_bb0460","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1093\/jnci\/djk178","article-title":"Oral sodium clodronate for nonmetastatic prostate cancer--results of a randomized double-blind placebo-controlled trial: Medical Research Council PR04 (ISRCTN61384873)","volume":"99","author":"Mason","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0465","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/8756-3282(93)90240-B","article-title":"Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss","volume":"14","author":"Giannini","year":"1993","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0470","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0029-7844(96)00171-8","article-title":"Continuous and cyclical clodronate therapies and bone density in postmenopausal bone loss","volume":"88","author":"Giannini","year":"1996","journal-title":"Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0475","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S8756-3282(98)00154-9","article-title":"Intramuscular clodronate therapy in postmenopausal osteoporosis","volume":"24","author":"Rossini","year":"1999","journal-title":"Bone"},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0480","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1002\/jbmr.5650100505","article-title":"Cyclical clodronate is effective in preventing postmenopausal bone loss: a comparative study with transcutaneous hormone replacement therapy","volume":"10","author":"Filipponi","year":"1995","journal-title":"J. Bone Miner. Res."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0485","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/8756-3282(95)00442-4","article-title":"Cyclical intravenous clodronate in postmenopausal osteoporosis: results of a long-term clinical trial","volume":"18","author":"Filipponi","year":"1996","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0490","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S8756-3282(99)00273-2","article-title":"Intermittent versus continuous clodronate administration in postmenopausal women with low bone mass","volume":"26","author":"Filipponi","year":"2000","journal-title":"Bone"},{"issue":"3\u20134","key":"10.1016\/j.bone.2020.115715_bb0495","first-page":"61","article-title":"Prevention with clodronate of osteoporosis secondary to inhaled corticosteroid treatment in patients with chronic asthmatic bronchitis","volume":"20","author":"Muratore","year":"2000","journal-title":"Int. J. Clin. Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.bone.2020.115715_bb0500","first-page":"33","article-title":"Effect of intramuscular clodronate on bone mass and metabolism in osteoporotic women","volume":"23","author":"Gnudi","year":"2001","journal-title":"Int. J. Tissue React."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0505","first-page":"430","article-title":"The effect of clodronate on bone mineral density and serum osteocalcin in postmenopausal women with osteopenia - a prospective, randomized, placebo-controlled study","volume":"8","author":"Napierala","year":"2006","journal-title":"Ortop. Traumatol. Rehabil."},{"issue":"10","key":"10.1016\/j.bone.2020.115715_bb0510","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1016\/j.cgh.2007.05.016","article-title":"A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease","volume":"5","author":"Abitbol","year":"2007","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0515","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.dld.2007.02.005","article-title":"A 4-year treatment with clodronate plus calcium and vitamin D supplements does not improve bone mass in primary biliary cirrhosis","volume":"39","author":"Floreani","year":"2007","journal-title":"Dig. Liver Dis."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0520","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s40261-013-0062-4","article-title":"Improved efficacy of intramuscular weekly administration of clodronate 200 mg (100 mg twice weekly) compared with 100 mg (once weekly) for increasing bone mineral density in postmenopausal osteoporosis","volume":"33","author":"Frediani","year":"2013","journal-title":"Clin. Drug Investig."},{"issue":"5202","key":"10.1016\/j.bone.2020.115715_bb0525","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/223211a0","article-title":"Prevention by a diphosphonate of immobilization \u201costeoporosis\u201d in rats","volume":"223","author":"Fleisch","year":"1969","journal-title":"Nature"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2020.115715_bb0530","first-page":"S63","article-title":"Effects of clodronate on immobilization bone loss","volume":"8","author":"Minaire","year":"1987","journal-title":"Bone"},{"issue":"10","key":"10.1016\/j.bone.2020.115715_bb0535","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1136\/adc.88.10.945","article-title":"Oral clodronate as treatment of osteogenesis imperfecta","volume":"88","author":"Ashford","year":"2003","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.bone.2020.115715_bb0540","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ejenta.2015.08.007","article-title":"Polyostotic fibrous dysplasia of the mandible and bony nasal septum with intracranial expansion","volume":"17","author":"Numminen","year":"2016","journal-title":"Egyptian Journal of Ear, Nose, Throat and Allied Sciences"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2020.115715_bb0545","first-page":"S69","article-title":"Clodronate in the medical management of hyperparathyroidism","volume":"8","author":"Hamdy","year":"1987","journal-title":"Bone"},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0550","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/BF03327373","article-title":"A single bisphosphonate infusion is associated with improved functional capacity in elderly subjects with primary hyperparathyroidism","volume":"15","author":"Ammann","year":"2003","journal-title":"Aging Clin. Exp. Res."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0555","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF02230335","article-title":"Transient osteoporosis of the hip: a densitometric study","volume":"15","author":"Varenna","year":"1996","journal-title":"Clin. Rheumatol."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0560","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1054\/ijom.2001.0061","article-title":"Disodium clodronate in the treatment of diffuse sclerosing osteomyelitis (DSO) of the mandible","volume":"30","author":"Montonen","year":"2001","journal-title":"Int. J. Oral Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0565","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1054\/ijom.2002.0401","article-title":"Successful management of severe facial pain in patients with diffuse sclerosing osteomyelitis (DSO) of the mandible using disodium clodronate","volume":"32","author":"Sugata","year":"2003","journal-title":"Int. J. Oral Maxillofac. Surg."},{"issue":"5","key":"10.1016\/j.bone.2020.115715_bb0570","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.oooo.2019.11.010","article-title":"Diffuse sclerosing osteomyelitis: a case series and literature review","volume":"129","author":"Matharu","year":"2019","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol."},{"issue":"6","key":"10.1016\/j.bone.2020.115715_bb0575","first-page":"1477","article-title":"Intravenous clodronate in the treatment of reflex sympathetic dystrophy syndrome. A randomized, double blind, placebo controlled study","volume":"27","author":"Varenna","year":"2000","journal-title":"J. Rheumatol."},{"issue":"4","key":"10.1016\/j.bone.2020.115715_bb0580","doi-asserted-by":"crossref","first-page":"300","DOI":"10.23736\/S0026-4806.18.05688-4","article-title":"Clodronate in the management of different musculoskeletal conditions","volume":"109","author":"Frediani","year":"2018","journal-title":"Minerva Med."},{"issue":"2","key":"10.1016\/j.bone.2020.115715_bb0585","first-page":"97","article-title":"Clodronate: new directions of use","volume":"12","author":"Frediani","year":"2015","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"10.1016\/j.bone.2020.115715_bb0590","article-title":"Pharmacology of bisphosphonates in pain","author":"Tzschentke","year":"2019","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.bone.2020.115715_bb0595","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/evj.13011","article-title":"Clodronate improves lameness in horses without changing bone turnover markers","volume":"51","author":"Mitchell","year":"2019","journal-title":"Equine Vet. J."},{"key":"10.1016\/j.bone.2020.115715_bb0600","doi-asserted-by":"crossref","first-page":"102874","DOI":"10.1016\/j.jevs.2019.102874","article-title":"What do we know about clodronate now? A Medical and Veterinary Perspective","volume":"88","author":"Markell","year":"2020","journal-title":"J. Equine Vet. Sci."},{"key":"10.1016\/j.bone.2020.115715_bb0605","first-page":"115711","article-title":"Bisphosphonates in veterinary medicine: the new horizon for use","volume":"142","author":"Suva","year":"2021","journal-title":"Bone (This Supplement)"},{"issue":"31","key":"10.1016\/j.bone.2020.115715_bb0610","doi-asserted-by":"crossref","first-page":"E6297","DOI":"10.1073\/pnas.1704847114","article-title":"Identification of a vesicular ATP release inhibitor for the treatment of neuropathic and inflammatory pain","volume":"114","author":"Kato","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.bone.2020.115715_bb0615","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206276","article-title":"Involvement of VNUT-exocytosis in transient receptor potential vanilloid 4-dependent ATP release from gastrointestinal epithelium","volume":"13","author":"Mihara","year":"2018","journal-title":"PLoS One"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220304956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328220304956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T03:42:14Z","timestamp":1762659734000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328220304956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":123,"alternative-id":["S8756328220304956"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2020.115715","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clodronate","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2020.115715","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115715"}}